Tuesday, October 2, 2012

EASD - Lixisenatide (Lyxumia) added to consistently titrated insulin glargine plus oral agents significantly improved HbA1c, reduced PPG and had a beneficial effect on weight

A randomized, double-blind, multicentre trial in Type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic agents assessed the efficacy and safety of lixisenatide (GLP-1) added on to titrated insulin glargine + metformin ± TZDs.



56% of the patients on lixisenatide patients achieved HbA1c < 7 as compared to 39% on insulin glargine alone. Glargine was initiated and titrated in a 12-week run-in phase to achieve fasting plasma glucose 4.4-5.6 mmol/L. 

Lixisenatide significantly improved 2-h postprandial glucose (PPG) after a standardized breakfast.  Compard to insulin glargine along,  Lixisenatide reduced 2hr PPG by a a mean of 3.16 mmol/L. Lixisenatide also had had a beneficial effect on body weight versus placebo. It reduced body weight by 0.89kg.